From molecular signatures to predictive biomarkers: Modeling disease pathophysiology and drug mechanism of action

Frontiers in Cell and Developmental Biology

Volumn 2, Issue AUG, 2014, Pages

  Heinzel, Andreas ^a   Perco, Paul ^a   Mayer, Gert ^b   Oberbauer, Rainer ^c   Lukas, Arno ^a   Mayer, Bernd ^a  

^a Emergentec Biodevelopment GmbH   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biomarker; Integration; Molecular model; Omics; Precision medicine; Systems biology; Systems pharmacology; Target

Indexed keywords

EID: 84937030092     PISSN: None     EISSN: 2296634X     Source Type: Journal    
DOI: 10.3389/fcell.2014.00037     Document Type: Article

References (59)

1. Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., and Holman, R. R. (2003). Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63, 225-232. doi: 10.1046/j.1523-1755.2003.00712.x
2. Adler, S. G., Schwartz, S., Williams, M. E., Arauz-Pacheco, C., Bolton, W. K., Lee, T., et al. (2010). Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin. J. Am. Soc. Nephrol. 5, 1420-1428. doi: 10.2215/CJN.09321209
3. Bader, G. D., and Hogue, C. W. V. (2003). An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 4:2. doi: 10.1186/1471-2105-4-2
4. Baelde, H. J., Eikmans, M., Doran, P. P., Lappin, D. W. P., de Heer, E., and Bruijn, J. A. (2004). Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am. J. Kidney Dis. 43, 636-650. doi: 10.1053/j.ajkd.2003.12.028
5. Berthier, C. C., Zhang, H., Schin, M., Henger, A., Nelson, R. G., Yee, B., et al. (2009). Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58, 469-477. doi: 10.2337/db08-1328
6. Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H. H., et al. (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869. doi: 10.1056/NEJMoa011161
7. Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., et al. (2006). Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst. 98, 1183-1192. doi: 10.1093/jnci/djj329
8. Cohen, C. D., Lindenmeyer, M. T., Eichinger, F., Hahn, A., Seifert, M., Moll, A. G., et al. (2008). Improved elucidation of biological processes linked to diabetic nephropathy by single probe-based microarray data analysis. PLoS ONE 3:e2937. doi: 10.1371/journal.pone.0002937
9. Croft, D., Mundo, A. F., Haw, R., Milacic, M., Weiser, J., Wu, G., et al. (2014). The Reactome pathway knowledgebase. Nucleic Acids Res. 42, D472-D477. doi: 10.1093/nar/gkt1102
10. De Leon, J. (2012). Evidence-based medicine versus personalized medicine: are they enemies? J. Clin. Psychopharmacol. 32, 153-164. doi: 10.1097/JCP.0b013e3182491383
11. Deshmukh, H. A., Palmer, C. N. A., Morris, A. D., and Colhoun, H. M. (2013). Investigation of known estimated glomerular filtration rate loci in patients with type 2 diabetes. Diabet. Med. 30, 1230-1235. doi: 10.1111/dme.12211
12. De Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G. L., Chin, M., Christ-Schmidt, H., et al. (2013). Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492-2503. doi: 10.1056/NEJMoa1306033
13. Dong, F. B., Sorensen, S. W., Manninen, D. L., Thompson, T. J., Narayan, V., Orians, C. E., et al. (2004). Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus. Pharmacoeconomics 22, 1015-1027. doi: 10.2165/00019053-200422150-00005
14. Fechete, R., Heinzel, A., Perco, P., Mönks, K., Söllner, J., Stelzer, G., et al. (2011). Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy. Proteomics Clin. Appl. 5, 354-366. doi: 10.1002/prca.201000136
15. Fechete, R., Heinzel, A., Soellner, J., Perco, P., Lukas, A., and Mayer, B. (2013). Using information content for expanding human protein coding gene interaction networks. J. Comput. Sci. Syst. Biol. 6, 73-82. doi: 10.4172/jcsb.1000102
16. Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., et al. (2013). Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 369, 1892-1903. doi: 10.1056/NEJMoa1303154
17. He, J. C., Chuang, P. Y., Ma'ayan, A., and Iyengar, R. (2012). Systems biology of kidney diseases. Kidney Int. 81, 22-39. doi: 10.1038/ki.2011.314
18. Heinzel, A., Fechete, R., Mühlberger, I., Perco, P., Mayer, B., and Lukas, A. (2013). Molecular models of the cardiorenal syndrome. Electrophoresis 34, 1649-1656. doi: 10.1002/elps.201200642
19. Heinzel, A., Fechete, R., Söllner, J., Perco, P., Heinze, G., Oberbauer, R., et al. (2012). Data graphs for linking clinical phenotype and molecular feature space. Int. J. Syst. Biol. Biomed. Technol. 1, 11-25. doi: 10.4018/ijsbbt.2012010102
20. Heinzel, A., Mühlberger, I., Fechete, R., Mayer, B., and Perco, P. (2014). Functional molecular units for guiding biomarker panel design. Methods Mol. Biol. 1159, 109-133. doi: 10.1007/978-1-4939-0709-0_7
21. Hellemons, M. E., Kerschbaum, J., Bakker, S. J. L., Neuwirt, H., Mayer, B., Mayer, G., et al. (2012). Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review. Diabet. Med. 29, 567-577. doi: 10.1111/j.1464-5491.2011.03437.x
22. Hernández-Presa, M., Bustos, C., Ortego, M., Tuñon, J., Renedo, G., Ruiz-Ortega, M., et al. (1997). Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95, 1532-1541
23. Hicks, D. G., and Kulkarni, S. (2008). HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am. J. Clin. Pathol. 129, 263-273. doi: 10.1309/99AE032R9FM8WND1
24. Himmelfarb, J., and Tuttle, K. R. (2013). New therapies for diabetic kidney disease. N. Engl. J. Med. 369, 2549-2550. doi: 10.1056/NEJMe1313104
25. Hollebecque, A., Massard, C., and Soria, J.-C. (2014). Implementing precision medicine initiatives in the clinic: a new paradigm in drug development. Curr. Opin. Oncol. 26, 340-346. doi: 10.1097/CCO.0000000000000077
26. James, L. R., Le, C., Doherty, H., Kim, H.-S., and Maeda, N. (2013). Connective tissue growth factor (CTGF) expression modulates response to high glucose. PLoS ONE 8:e70441. doi: 10.1371/journal.pone.0070441
27. Johnson, J. A. (2001). Drug target pharmacogenomics: an overview. Am. J. Pharmacogenomics 1, 271-281. doi: 10.2165/00129785-200101040-00004
28. Kanehisa, M., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., and Tanabe, M. (2014). Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 42, D199-D205. doi: 10.1093/nar/gkt1076
29. Kashiwagi, M., Masutani, K., Shinozaki, M., and Hirakata, H. (2002). MCP-1 and RANTES are expressed in renal cortex of rats chronically treated with nitric oxide synthase inhibitor. Involvement in macrophage and monocyte recruitment. Nephron 92, 165-173. doi: 10.1159/000064454
30. KDIGO Board Members. (2013). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1-150. doi: 10.1038/kisup.2012.73
31. Kerrien, S., Aranda, B., Breuza, L., Bridge, A., Broackes-Carter, F., Chen, C., et al. (2012). The IntAct molecular interaction database in 2012. Nucleic Acids Res. 40, D841-D846. doi: 10.1093/nar/gkr1088
32. Komorowsky, C. V., Brosius, F. C., Pennathur, S., and Kretzler, M. (2012). Perspectives on systems biology applications in diabetic kidney disease. J. Cardiovasc. Transl. Res. 5, 491-508. doi: 10.1007/s12265-012-9382-7
33. LaFramboise, W. A., Dhir, R., Kelly, L. A., Petrosko, P., Krill-Burger, J. M., Sciulli, C. M., et al. (2012). Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography. BMC Med. 10:157. doi: 10.1186/1741-7015-10-157
34. Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., et al. (2014). DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091-D1097. doi: 10.1093/nar/gkt1068
35. Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., et al. (2001). Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860. doi: 10.1056/NEJMoa011303
36. Loeffler, I., and Wolf, G. (2014). Transforming growth factor-β and the progression of renal disease. Nephrol. Dial. Transplant. 29(Suppl. 1), i37-i45. doi: 10.1093/ndt/gft267
37. Mann, J. F. E., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., et al. (2008). Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547-553. doi: 10.1016/S0140-6736(08)61236-2
38. Mayer, P., Mayer, B., and Mayer, G. (2012). Systems biology: building a useful model from multiple markers and profiles. Nephrol. Dial. Transplant. 27, 3995-4002. doi: 10.1093/ndt/gfs489
39. McLennan, S. V., Abdollahi, M., and Twigg, S. M. (2013). Connective tissue growth factor, matrix regulation, and diabetic kidney disease. Curr. Opin. Nephrol. Hypertens. 22, 85-92. doi: 10.1097/MNH.0b013e32835b4889
40. Mirnezami, R., Nicholson, J., and Darzi, A. (2012). Preparing for precision medicine. N. Engl. J. Med. 366, 489-491. doi: 10.1056/NEJMp1114866
41. Mühlberger, I., Mönks, K., Fechete, R., Mayer, G., Oberbauer, R., Mayer, B., et al. (2012). Molecular pathways and crosstalk characterizing the cardiorenal syndrome. OMICS 16, 105-112. doi: 10.1089/omi.2011.0121
42. Nkuipou-Kenfack, E., Duranton, F., Gayrard, N., Argilés, A., Lundin, U., Weinberger, K. M., et al. (2014). Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease. PLoS ONE 9:e96955. doi: 10.1371/journal.pone.0096955
43. Pammolli, F., Magazzini, L., and Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10, 428-438. doi: 10.1038/nrd3405
44. Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., and Hollenberg, N. K. (2008). Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446. doi: 10.1056/NEJMoa0708379
45. Pena, M. J., Lambers Heerspink, H. J., Hellemons, M. E., Friedrich, T., Dallmann, G., Lajer, M., et al. (2014). Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. Diabet. Med. 31, 1138-1147. doi: 10.1111/dme.12447
46. Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., et al. (2011). Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327-336. doi: 10.1056/NEJMoa1105351
47. Rodríguez-Iturbe, B., and García García, G. (2010). The role of tubulointerstitial inflammation in the progression of chronic renal failure. Nephron Clin. Pract. 116, c81-c88. doi: 10.1159/000314656
48. Roscioni, S. S., de Zeeuw, D., Hellemons, M. E., Mischak, H., Zürbig, P., Bakker, S. J. L., et al. (2013). A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 56, 259-267. doi: 10.1007/s00125-012-2755-2
49. Roscioni, S. S., Lambers Heerspink, H. J., and de Zeeuw, D. (2014). Microalbuminuria: target for renoprotective therapy PRO. Kidney Int. 86, 40-49. doi: 10.1038/ki.2013.490
50. Rudnicki, M., Perco, P., Enrich, J., Eder, S., Heininger, D., Bernthaler, A., et al. (2009). Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab. Invest. 89, 337-346. doi: 10.1038/labinvest.2008.158
51. Ruggenenti, P., Perna, A., Gherardi, G., Gaspari, F., Benini, R., and Remuzzi, G. (1998). Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352, 1252-1256
52. Sayers, E. W., Barrett, T., Benson, D. A., Bryant, S. H., Canese, K., Chetvernin, V., et al. (2009). Database resources of the national center for biotechnology information. Nucleic Acids Res. 37, D5-D15. doi: 10.1093/nar/gkn741
53. Stark, C., Breitkreutz, B.-J., Reguly, T., Boucher, L., Breitkreutz, A., and Tyers, M. (2006). BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 34, D535-D539. doi: 10.1093/nar/gkj109
54. Tan, S. M., and de Haan, J. B. (2014). Combating oxidative stress in diabetic complications with Nrf2 activators: how much is too much? Redox Rep. 19, 107-117. doi: 10.1179/1351000214Y.0000000087
55. Thomas, P. D., Campbell, M. J., Kejariwal, A., Mi, H., Karlak, B., Daverman, R., et al. (2003). PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 13, 2129-2141. doi: 10.1101/gr.772403
56. Trusheim, M. R., Burgess, B., Hu, S. X., Long, T., Averbuch, S. D., Flynn, A. A., et al. (2011). Quantifying factors for the success of stratified medicine. Nat. Rev. Drug Discov. 10, 817-833. doi: 10.1038/nrd3557
57. U.S. Food and Drug Administration. (2014). Table of Pharmacogenomic Biomarkers in Drug Labeling [Internet]
58. Woroniecka, K. I., Park, A. S. D., Mohtat, D., Thomas, D. B., Pullman, J. M., and Susztak, K. (2011). Transcriptome analysis of human diabetic kidney disease. Diabetes 60, 2354-2369. doi: 10.2337/db10-1181
59. Zürbig, P., Jerums, G., Hovind, P., Macisaac, R. J., Mischak, H., Nielsen, S. E., et al. (2012). Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 61, 3304-3313. doi: 10.2337/db12-0348